Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Companies that recently reported results, including Advantest and ASML Holding, have indicated that demand remains strong ...

Amy Schumer lost 30 pounds using Ozempic, but experienced negative side effects. She was "bedridden" and didn't have energy. Amy has a gene that makes her "prone to nausea," which she believes is ...

Global oil demand seen growing by 700,000 to 1.3 mln ... potentially boosting overall oil supply, analysts noted. "Given the Trump campaign's stated focus on lowering energy prices there could ...

The company's key products, including Ozempic (semaglutide ... on the expanding GLP-1 market and meet the increasing demand for anti-obesity medications. Want deeper insights?